Spotify Co-Founder’s Neko Health Expands Body Scans to the US

Neko Health, the preventative diagnostics startup co-founded by Spotify co-founders David Ek and Hjalmar Nilsonne, has officially entered the United States market with its flagship body scan technology now available in New York. Backed by a global waitlist exceeding 300,000 individuals and supported by nearly $1 billion in total funding, the company aims to revolutionize preventive healthcare by offering comprehensive, non-invasive physiological screening. The scan utilizes advanced computer vision and artificial intelligence to analyze blood markers, skin conditions, and metabolic health within a single hour-long session. The service is priced at $500 per session and is not currently covered by traditional insurance, though it qualifies as a Health Savings Account eligible expense. This direct-to-consumer pricing model is designed to bypass the cost barriers that historically limit preventive care utilization in the United States. Farooq Abbasi, a managing partner at Preface Ventures and early investor, emphasized that Neko Health delivers actionable clinical insights rather than functioning as a wellness trend. Abbasi, who has utilized the service multiple times, noted the technology’s rapid evolution from an initial 15 biomarkers to 55 in recent iterations, underscoring the company’s commitment to continuous diagnostic improvement. The expansion into New York represents a strategic move to address systemic inefficiencies in the American healthcare landscape. Investors and company leadership anticipate that widespread adoption of accessible preventative screening could reduce long-term medical expenditures and improve population health outcomes. To support this goal, Neko Health is actively pursuing a multi-clinic rollout across the country, with Abbasi advocating for broader distribution of the technology. The company’s approach leverages AI-driven data analysis to provide users with personalized health recommendations, positioning itself at the intersection of digital health and computational biology. Despite the optimistic trajectory, Neko Health faces significant operational and regulatory challenges as it scales its US operations. Gaining full federal regulatory approval for its diagnostic claims and establishing a robust network of authorized scanning centers remain critical milestones. Nevertheless, the startup maintains that its technology addresses a fundamental market gap by making comprehensive health monitoring both affordable and proactive. As venture capital continues to flow into the digital health sector, Neko Health’s expansion signals a growing industry shift toward early detection and data-driven preventative care. The company’s next phase will focus on securing regulatory clearances, optimizing clinic infrastructure, and expanding its biomarker database to solidify its position as a leader in accessible diagnostic innovation.